UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported):  June 11, 2020

vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction

of incorporation)

001-37524

(Commission File No.)

47-3916571
(IRS Employer
Identification No.)

 

3980 Premier Drive, Suite 310

High Point, NC 27265

(Address of principal executive offices)

 

(336) 841-0300

(Registrant’s telephone number, including area code)  

NOT APPLICABLE

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, par value $0.01 per share

VTVT

NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 


Item 5.07 Submission of Matters to a Vote of Security Holders

On June 11, 2020, vTv Therapeutics Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”).  The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

 

(1)

The Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a term to expire at the Company’s 2021 annual meeting of stockholders or until their successors are duly elected and qualified based on the following results of the voting:

Director Nominee

  

For

 

  

Against

 

  

Withheld

 

  

Broker Non-Votes

 

 

Jeffrey B. Kindler

  

 

59,531,174

  

  

 

  

  

 

150,874

  

  

 

5,947,754

 

  

John A. Fry

  

 

59,593,955

  

  

 

  

  

 

88,093

  

  

 

5,947,754

 

  

Hersh Kozlov

  

 

59,543,228

  

  

 

  

  

 

138,820

  

  

 

5,947,754

 

  

Paul G. Savas

 

 

59,556,857

 

 

 

 

 

 

125,191

 

 

 

5,947,754

 

 

Noel J. Spiegel

 

 

59,603,564

 

 

 

 

 

 

78,484

 

 

 

5,947,754

 

 

Howard L. Weiner

 

 

59,602,155

 

 

 

 

 

 

79,893

 

 

 

5,947,754

 

 

 

 

(2)

An amendment to the Company’s 2015 Omnibus Equity Incentive Plan (the “Omnibus Incentive Plan”) to increase the number of authorized shares reserved for issuance under the Omnibus Incentive Plan was approved based on the following results of the voting:

For

 

  

Against

 

  

Withheld

 

  

Broker Non-Votes

 

 

 

59,156,032

  

  

 

454,594

  

  

 

71,422

  

  

 

5,947,754

 

  

 

 

(3)

The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 was ratified based on the following results of the voting:

For

 

 

Against

 

 

Abstain

 

 

65,258,211

  

 

 

328,705

  

 

 

42,886

  

 

 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

VTV THERAPEUTICS INC.

By:

/s/ Rudy C. Howard

Name:

Rudy C. Howard

Title:

Chief Financial Officer

 

Dated: June 15, 2020

 

 

 

 

 

vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more vTv Therapeutics Charts.
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more vTv Therapeutics Charts.